Effects of plasma lipoproteins on the production of superoxide anion by human polymorphonuclear leukocytes in vitro

The role and regulation of phospholipase D in metabolic disorders

Phospholipase D (PLD) is an enzyme that catalyzes the hydrolysis of phosphatidylcholine into phosphatidic acid and free choline. In mammals, PLD exists in two well-characterized isoforms, PLD1 and PLD2, and it plays pivotal roles as signaling mediators in various cellular functions, such as cell survival, differentiation, and migration. These isoforms are predominantly expressed in diverse cell types, including many immune cells, such as monocytes and macrophages, as well as non-immune cells, such as epithelial and endothelial cells. Several previous studies have revealed that the stimulation of these cells leads to an increase in PLD expression and its enzymatic products, potentially influencing the pathological responses in a wide spectrum of diseases. Metabolic diseases, exemplified by conditions, such as diabetes, obesity, hypertension, and atherosclerosis, pose significant global health challenges. Abnormal activation or dysfunction of PLD emerges as a potential contributing factor to the pathogenesis and progression of these metabolic disorders. Therefore, it is crucial to thoroughly investigate and understand the intricate relationship between PLD and metabolic diseases. In this review, we provide an in-depth overview of the functional roles and molecular mechanisms of PLD involved in metabolic diseases. By delving into the intricate interplay between PLD and metabolic disorders, this review aims to offer insights into the potential therapeutic interventions.

The value of C-reactive protein in symptomatic versus asymptomatic carotid artery stenosis

Inflammatory markers may help establish the diagnosis of carotid atherosclerotic disease and predict the progression and outcomes. We evaluated inflammatory markers in symptomatic and asymptomatic patients with moderate to severe carotid artery stenosis, including high-sensitivity C-reactive protein (hs-CRP), leukocyte count, leukocyte subgroups and erythrocyte sedimentation rate. There were 32 symptomatic and 16 asymptomatic patients (age ≥50 years) with moderate to severe carotid stenosis detected by color Doppler ultrasonography, and 22 individuals without atherosclerotic findings on Doppler ultrasonography. The mean hs-CRP was significantly greater in the symptomatic (p = 0.001) and asymptomatic (p < 0.001) patients than control subjects; there was no significant difference between symptomatic and asymptomatic patients in mean hs-CRP values. Compared with control subjects, asymptomatic patients had greater mean leukocyte count (p = 0.016). Compared with control subjects, symptomatic patients had greater mean neutrophil count (p = 0.012), monocyte count (p = 0.021) and erythrocyte sedimentation rate (p = 0.001). The hs-CRP was associated with moderate to severe carotid artery stenosis, but it did not differentiate symptomatic and asymptomatic patients.

Hypoxia-induced chemiluminescence in human leukocytes: the role of Ca2+

Circumstantial evidence suggests that in vivo hypoxia can activate human leukocytes to release a host of mediators including oxygen free radicals. Endothelial cells have always been presumed to play an important role in hypoxia-induced leukocyte activation. The primary aim of this study was to determine whether acute exposure of whole blood to a hypoxic mixture could stimulate the production of oxygen free radicals in the absence of endothelial cells, and to determine the role of Ca2+ in this process. Freshly drawn whole blood was obtained by venepuncture from 30 healthy volunteers. Exposure of blood to 6% O2 in a purpose built environmental chamber for periods of 8, 10, 15, 30, and 45 min resulted in a significant increase in the production of oxygen free radicals. This response was significantly increased after a 10-min incubation with the Ca2+ ionophore (A23187), supporting the idea that the influx of extracellular Ca2+ is an important step in the process. Incubation of human leukocytes with verapamil (10 min) and subsequent exposure to hypoxia resulted in the significantly reduction in hypoxia-induced production of oxygen free radicals at 15 min and a paradoxical increase at 30- and 45-min exposures. The significance of the results is discussed.

Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: role of cAMP

Vascular smooth muscle is now recognized as an important site of mediator generation under inflammatory conditions. Indeed, the release of leukocyte activators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-8, by human arterial smooth muscle cells has recently been demonstrated. However, the potential for venous cells to release GM-CSF has not been addressed. We have shown that human vascular smooth muscle cells express the "inflammatory" form of cyclooxygenase (COX), cyclooxygenase-2 (COX-2), when stimulated with cytokines. In some nonvascular cell types, the COX activity has been shown to regulate the release of GM-CSF and IL-8, although the nature of the isoform responsible was not addressed. We show that human venous smooth muscle cells, like their arterial counterparts, release GM-CSF after stimulation with IL-1beta. Similarly, both cell types released IL-8. Under the same conditions, we found that COX-2 activity suppressed GM-CSF, but not IL-8, release by both types of human vascular cells. Moreover, the prostacyclin mimetic, cicaprost, and the cAMP analogue, dibutyryl cAMP, inhibited GM-CSF release from these cells. These observations suggest that COX-2 activity suppresses GM-CSF release via a cAMP-dependent pathway in human vascular cells and illustrates a novel mechanism by which this enzyme can modulate immune and inflammatory events.

13-HPODE and 13-HODE modulate cytokine-induced expression of endothelial cell adhesion molecules differently

Expression of cellular adhesion molecules (CAMs) at endothelial surfaces represents a physiological response to vascular damage and mediates the initiation of inflammation and possibly of atherogenesis. The cytokines TNF alpha and IL-1 are potent inducers of CAMs in endothelial cells. Reactive oxygen species comprising lipid oxidation products have been implicated in the signaling pathways of both TNF alpha and IL-1 and accordingly could modulate atherogenic events. We, therefore, investigated the potential role of the lipoxygenase product, 13-hydroperoxyoctadecadienoic acid (13-HPODE), which has also been identified in oxidized low density lipoproteins on CAM expression in HUVEC. 13-HPODE induced the expression of ICAM-1 in a concentration dependent manner up to 75 microM. Higher concentrations were toxic. Similar effects were observed with H2O2 and phosphatidylcholine hydroperoxide. VCAM-1 and E-selectin were not induced by 13-HPODE. 13-HPODE administered simultaneously with IL-1 or TNF alpha induced ICAM-1 additively, suggesting that hydroperoxides and cytokines act on the same signaling pathways. In contrast, pretreatment of cells with 50 microM 13-HPODE for 1 hour rather inhibited subsequent cytokine-induced ICAM-1 and E-selectin expression. Surprisingly, the reduction product of 13-HPODE, 13-hydroxyoctadecadienoic acid (13-HODE) proved to be an even better inducer of ICAM-1 than 13-HPODE. Pretreatment with 13-HODE did not show any inhibitory effect on ICAM-1 expression. Our data show that lipoxygenase products differentially affect CAM expression. 13-HPODE is stimulatory by itself and can positively or negatively affect cytokine signaling depending on time of exposure. 13-HODE induces CAM expression by itself but does not inhibit cytokine signaling. Thus, the interplay of lipoxygenase products with proinflammatory cytokines can not simply be explained by an oxidant-mediated facilitation of cytokine signaling.